Article
Oncology
Yi-Chia Su, Chih-Chien Wu, Chien-Chou Su, Meng-Che Hsieh, Ching-Lan Cheng, Yea-Huei Kao Yang
Summary: This study assessed the effectiveness of bevacizumab and cetuximab therapies in patients with metastatic colorectal cancer who did not undergo primary tumor resection. The results showed that cetuximab-based therapy had significantly better survival and conversion surgery rates compared to bevacizumab-based therapy in these patients.
Article
Medicine, General & Internal
Kishan K. Patel, Stacey Stein, Jill Lacy, Mark O'Hara, Scott F. Huntington
Summary: The study found that doublet therapy for metastatic BRAF variant colorectal cancer may not be cost-effective. Cost-effectiveness requires consideration, especially when combining new therapies with non-cost-effective treatments.
Article
Medicine, General & Internal
Gerald W. Prager, Julien Taieb, Marwan Fakih, Fortunato Ciardiello, Eric Van Cutsem, Elena Elez, Felipe M. Cruz, Lucjan Wyrwicz, Daniil Stroyakovskiy, Zsuzsanna Papai, Pierre-Guillaume Poureau, Gabor Liposits, Chiara Cremolini, Igor Bondarenko, Dominik P. Modest, Karim A. Benhadji, Nadia Amellal, Catherine Leger, Loick Vidot, Josep Tabernero
Summary: In this study, researchers found that treatment with trifluridine-tipiracil plus bevacizumab could prolong overall survival in patients with metastatic colorectal cancer compared to trifluridine-tipiracil alone.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Marla Lipsyc-Sharf, Fang-Shu Ou, Matthew B. Yurgelun, Douglas A. Rubinson, Deborah Schrag, Shaker R. Dakhil, Philip J. Stella, Douglas J. Weckstein, Donald B. Wender, Meredith Faggen, Tyler J. Zemla, Erica N. Heying, Samantha R. Schuetz, Stephanie Noble, Jeffrey A. Meyerhardt, Tanios Bekaii-Saab, Charles S. Fuchs, Kimmie Ng
Summary: The study investigated the efficacy of combining bevacizumab with irinotecan and cetuximab in patients with irinotecan-refractory metastatic colorectal cancer. Although there was no significant difference in progression-free survival between the two treatment groups, there was a statistically significant improvement in overall survival favoring the group that received bevacizumab in addition to irinotecan and cetuximab. Further investigation on this combination therapy is warranted.
Article
Pharmacology & Pharmacy
Changjing Cai, Qingqing Luo, Yihan Liu, Yinghui Peng, Xiangyang Zhang, Zhaohui Jiang, Ziyang Feng, Yaru Qi, Yan Gao, Yongting Liu, Ping Liu, Yihong Chen, Cao Guo, Hong Shen, Shan Zeng, Ying Han
Summary: This study conducted a comprehensive analysis of treatment regimens for left-sided RAS wild-type metastatic colorectal cancer (mCRC) and found that the double-drug regimen plus cetuximab/panitumumab was more effective and safer than the double-drug and triple-drug regimens with bevacizumab.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Elena Elez, Javier Ros, Jose Fernandez, Guillermo Villacampa, Ana Belen Moreno-Cardenas, Carlota Arenillas, Kinga Bernatowicz, Raquel Comas, Shanshan Li, David Philip Kodack, Roberta Fasani, Ariadna Garcia, Javier Gonzalo-Ruiz, Alejandro Piris-Gimenez, Paolo Nuciforo, Grainne Kerr, Rossana Intini, Aldo Montagna, Marco Maria Germani, Giovanni Randon, Ana Vivancos, Ron Smits, Diana Graus, Raquel Perez-Lopez, Chiara Cremolini, Sara Lonardi, Filippo Pietrantonio, Rodrigo Dienstmann, Josep Tabernero, Rodrigo A. Toledo
Summary: In colorectal cancer patients, inactivating mutations in the RNF43 gene are associated with patients' response rates and survival outcomes to anti-BRAF/EGFR therapy. This suggests that the status of the RNF43 gene may serve as a predictive biomarker for patients' clinical outcomes.
Article
Oncology
Marinde J. G. Bond, Karen Bolhuis, Olaf J. L. Loosveld, Jan Willem B. de Groot, Helga Droogendijk, Helgi H. Helgason, Mathijs P. Hendriks, Joost M. Klaase, Geert Kazemier, Mike S. L. Liem, Arjen M. Rijken, Cornelis Verhoef, Johannes H. W. de Wilt, Koert P. Jong, Michael F. Gerhards, Martinus J. van Amerongen, Marc R. W. Engelbrecht, Krijn P. van Lienden, I. Quintus Molenaar, Bart de Valk, Brigitte C. M. Haberkorn, Emile D. Kerver, Frans Erdkamp, Robbert J. van Alphen, Danielle Mathijssen-van Stein, Aysun Komurcu, Marta Lopez-Yurda, Rutger-Jan Swijnenburg, Cornelis J. A. Punt, Dutch Colorectal Canc Study Grp
Summary: This study compared the efficacy of different induction regimens in patients with initially unresectable colorectal cancer liver metastases. The results showed that FOLFOXIRI-bevacizumab was the preferred treatment for patients with right-sided primary tumor or RAS/BRAFV600E mutation, while the addition of panitumumab to FOLFOX or FOLFIRI in patients with left-sided and RAS/BRAFV600E wild-type tumor showed no clinical benefit but more toxicity.
Article
Oncology
Chunlong Huang, Xiaoyuan Gu, Xianshang Zeng, Baomin Chen, Weiguang Yu, Meiji Chen
Summary: The study demonstrated that CET showed superior survival benefit compared to BEV, with fewer tolerable adverse events.
Article
Oncology
Thierry Andre, Mayur Amonkar, Josephine M. Norquist, Kai-Keen Shiu, Tae Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis J. A. Punt, Denis Smith, Rocio Garcia-Carbonero, Isabel Sevilla, Christelle de la Fouchardiere, Fernando Rivera, Elena Elez, Luis A. Diaz Jr, Takayuki Yoshino, Eric Van Cutsem, Ping Yang, Mohammed Farooqui, Dung T. Le
Summary: The KEYNOTE-177 study found that pembrolizumab monotherapy significantly improved progression-free survival in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer compared to chemotherapy as first-line treatment, with clinically meaningful benefits. Health-related quality of life analyses further supported these findings.
Article
Oncology
Yu-Wen Zhou, Yi-Xiu Long, Ye Chen, Ji-Yan Liu, Dan Pu, Jia-Yan Huang, Feng Bi, Qiu Li, Hong-Feng Gou, Meng Qiu
Summary: The study compared the efficacy of first-line bevacizumab plus chemotherapy and cetuximab plus chemotherapy in metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component. The results showed that bevacizumab-based chemotherapy was associated with significantly better overall survival in patients with mucinous adenocarcinoma or mucinous component, regardless of tumor sites.
Article
Medicine, Research & Experimental
Shuosha Li, Huabin Hu, Dong Ding, Youwen Zhu, Jin Huang
Summary: The study evaluated the cost-effectiveness of BEC, EC, and CI/CF in patients with BRAF V600E-mutated mCRC after first- and second-line therapy based on BEACON trial outcomes data. Results showed that BEC and EC were not cost-effective regimens for patients with pre-treated mCRC with BRAF V600E mutation.
ADVANCES IN THERAPY
(2021)
Review
Pharmacology & Pharmacy
Yuying Cui, Yingxue Guo
Summary: This meta-analysis found that compared to cetuximab, bevacizumab treatment for advanced colorectal cancer can increase disease control rate, prolong overall survival, and reduce the incidence of skin disorders.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY
(2022)
Article
Multidisciplinary Sciences
Alexander J. Ohnmacht, Arndt Stahler, Sebastian Stintzing, Dominik P. Modest, Julian W. Holch, C. Benedikt Westphalen, Linus Hoelzel, Marisa K. Schuebel, Ana Galhoz, Ali Farnoud, Minhaz Ud-Dean, Ursula Vehling-Kaiser, Thomas Decker, Markus Moehler, Matthias Heinig, Volker Heinemann, Michael P. Menden
Summary: Precision medicine has revolutionized cancer treatments, but actionable biomarkers are still rare. In this study, the authors develop a framework called OncoBird to analyze the molecular and biomarker landscape of randomized controlled clinical trials, and apply it to a phase III trial investigating metastatic colorectal carcinoma patients.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Arndt Stahler, Volker Heinemann, Julian Walter Holch, Jobst Christian von Einem, Christoph Benedikt Westphalen, Kathrin Heinrich, Laura Schlieker, Ivan Jelas, Annabel Helga Sophie Alig, Laura Elisabeth Fischer, Lena Weiss, Dominik Paul Modest, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Markus Moehler, Florian Kaiser, Thomas Kirchner, Andreas Jung, Sebastian Stintzing
Summary: The study found that patients with mCRC who received cetuximab had higher objective response rate and overall survival. New mutations were observed in 18 patients after conversion therapy. Changes during cetuximab treatment were mainly gains, while losses were mainly observed during bevacizumab treatment.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Medicine, General & Internal
Ozan Yazici, Gokhan Ucar, Osman Sutcuoglu, Nazim Serdar Turhal, Birol Yildiz, Michalis Karamouzis, Sinan Yavuz, Nuri Karadurmus, Nurullah Zengin, Ravit Geva, Huseyin Abali
Summary: This multinational registry study evaluated the real-life data on the survival of patients with metastatic colorectal cancer (mCRC). The study found that factors such as the patient's performance status, tumor location, and number of metastatic lesions at the time of diagnosis have an impact on the prognosis of mCRC.
CURRENT MEDICAL RESEARCH AND OPINION
(2022)